The Translational Breast Cancer Research Consortium (TBCRC) plans to initiate the Treatment of ADC-Refractory Breast CancEr Dato-DXd or T-DXd (TRADE-DXd) trial, which will include patients with HER2-low ABC, 0–1 prior lines of therapy, and no prior topo-1 inhibitors. The gene discussed is ERBB2; the disease is breast carcinoma.